What is William Blair’s Estimate for DVAX Q1 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at William Blair lowered their Q1 2025 EPS estimates for shares of Dynavax Technologies in a research note issued on Friday, February 21st. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn $0.03 per share for the quarter, down from their previous forecast of $0.04. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $13.33 on Monday. The stock has a fifty day simple moving average of $12.82 and a 200-day simple moving average of $12.04. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.75 billion, a PE ratio of 74.06 and a beta of 1.32. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $14.05.

Institutional Trading of Dynavax Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning grew its holdings in shares of Dynavax Technologies by 77.2% in the third quarter. Creative Planning now owns 26,817 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 11,682 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Dynavax Technologies in the 3rd quarter valued at approximately $8,291,000. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Dynavax Technologies by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 25,204 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 9,827 shares during the period. Finally, US Bancorp DE increased its position in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the period. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.